Showing 15 posts of 64 posts found.

Senate puts forward bipartisan bill to lower price of drugs

July 24, 2019
Research and Development PBMs, Senate, USA, access, bipartisan, pharma, pricing

The Senate Finance Committee has introduced a bipartisan bill that aimed at lowering the prices Medicare pays for pharmaceutical drugs. …


Trump says executive order will ensure US will pay lowest prices in the world for drugs

July 8, 2019
Sales and Marketing Trump, US, executive order, pharma, politics, pricing

President Donald Trump has said that the White House is working on a ‘favoured nation clause’ to ensure the United …


Prices hiked on 3,400 drugs in first half of 2019

July 4, 2019
Research and Development, Sales and Marketing abstruse, access, generics, pharma, prescription, pricing

There have been price hikes on more than 3,400 drugs in the United States in the first six months of …


MPs discuss breaking Vertex’s IP rights to bring Orkambi to UK

June 11, 2019
Research and Development Orkambi, Vertex, access, house of commons, pharma, pricing

MPs yesterday discussed circumventing Vertex’s patent on cystic fibrosis medicine Orkambi (Lumacaftor/ivacaftor) as a means of breaking the deadlock and …


Top Ten most popular articles on this week!

May 31, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, FDA, GSK, Novartis, Pfizer, environment, opioids, pharma, pricing

The pharmaceutical industry is a big polluter than the automotive industry. This was our top story this week. The findings …


UK government refuses to sign up to WHO pricing transparency resolution

May 29, 2019
Research and Development WHA, WHO, access, health UK, pharma, pricing

The UK government has refused to sign up to a global resolution on transparency in drug pricing which urges governments …


Novartis’ $2.15m SMA drug Zolgensma becomes most expensive FDA-approved therapy

May 28, 2019
Manufacturing and Production AveXis, FDA, Zolgensma, access, drugs, pricing, sma

The FDA has approved Novartis subsidiary AveXis’ $2.15 million gene therapy Zolgensma for children with spinal muscular atrophy (SMA). The …


US States allege 20 generic drugmakers fixed prices of generic drugs

May 13, 2019
Sales and Marketing competition, generics, markets, price fixing, price-fixing, pricing

Forty-four US States have filed a lawsuit against 20 generic drugmakers – including Teva Pharmaceuticals – over allegations the firms …

The price of access: Can the NHS afford Orkambi?

April 29, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, NHS, NICE, Orkambi, UK, Vertex, access, cystic fibrosis, feature, pharma, pricing

The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in …

ICR calls for faster access to innovative cancer drugs

April 25, 2019
Medical Communications, Research and Development, Sales and Marketing Cancer, ICR, R&D, access, cancer drugs, incentives, innovation, oncology, pricing

The Institute of Cancer Research (ICR) has called for faster access to innovative cancer drugs in the UK. The call …

Indian government set to colour code generic medicines

March 4, 2019
Sales and Marketing India, Indian health, costs, generic medicines, pricing, sales

As part of an effort to promote low cost medicines, the Indian government has announced plans to colour code generic …

J&J to include prices in drug ads on TV

February 8, 2019
Medical Communications J&J, JJ, Johnson & Johnson, Trump, pharma, pricing

US multinational Johnson & Johnson has announced that it will include the price of its medicines in TV commercials for …


Pharma chiefs will testify at Senate hearing on rising drug prices

February 7, 2019
Sales and Marketing CEO, J&J, JJ, Pfizer, Sanofi, Senate, pharma, pricing

The Chief Executives of Pfizer, Sanofi and Bristol-Myers Squibb have said that they will join four other pharma execs in …


Sanders calls on Catalyst pharma to justify $375,000 price tag for rare disease drug which was once free

February 5, 2019
Manufacturing and Production Catalyst Pharmaceuticals, Jacobus Pharmaceuticals, Sanders, USA, pharma, pricing

Shares in Catalyst Pharmaceuticals plummeted Monday, after US Senator Bernie Sanders sent the firm a letter asking them to justify …

Cost of insulin doubled between 2012 and 2016

January 23, 2019
Research and Development USA, healthcare, insulin, insurance, pricing

The cost of insulin almost doubled in the United States between 2012 and 2016, according to a report by the …

Latest content